Literature DB >> 33585251

MYCN Function in Neuroblastoma Development.

Jörg Otte1, Cecilia Dyberg1, Adena Pepich1, John Inge Johnsen1.   

Abstract

Dysregulated expression of the transcription factor MYCN is frequently detected in nervous system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a single oncogenic driver inducing neoplastic transformation in neural crest-derived cells. This abnormal MYCN expression is one of the strongest predictors of poor prognosis. It is present at diagnosis and is never acquired during later tumorigenesis of MYCN non-amplified neuroblastoma. This suggests that increased MYCN expression is an early event in these cancers leading to a peculiar dysregulation of cells that results in embryonal or cancer stem-like qualities, such as increased self-renewal, apoptotic resistance, and metabolic flexibility.
Copyright © 2021 Otte, Dyberg, Pepich and Johnsen.

Entities:  

Keywords:  MYCN; cancer stem cell; childhood cancer; neural crest; neuroblastoma

Year:  2021        PMID: 33585251      PMCID: PMC7873735          DOI: 10.3389/fonc.2020.624079

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  116 in total

1.  Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles.

Authors:  A Nagy; C Moens; E Ivanyi; J Pawling; M Gertsenstein; A K Hadjantonakis; M Pirity; J Rossant
Journal:  Curr Biol       Date:  1998-05-21       Impact factor: 10.834

Review 2.  Target gene-independent functions of MYC oncoproteins.

Authors:  Apoorva Baluapuri; Elmar Wolf; Martin Eilers
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

3.  HIF1α induced switch from bivalent to exclusively glycolytic metabolism during ESC-to-EpiSC/hESC transition.

Authors:  Wenyu Zhou; Michael Choi; Daciana Margineantu; Lilyana Margaretha; Jennifer Hesson; Christopher Cavanaugh; C Anthony Blau; Marshall S Horwitz; David Hockenbery; Carol Ware; Hannele Ruohola-Baker
Journal:  EMBO J       Date:  2012-03-23       Impact factor: 11.598

4.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Authors:  Fredrik J Swartling; Vasil Savov; Anders I Persson; Justin Chen; Christopher S Hackett; Paul A Northcott; Matthew R Grimmer; Jasmine Lau; Louis Chesler; Arie Perry; Joanna J Phillips; Michael D Taylor; William A Weiss
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

5.  Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

Authors:  Sandrine Valsesia-Wittmann; Maud Magdeleine; Sébastien Dupasquier; Elisabeth Garin; Anne-Catherine Jallas; Valérie Combaret; Alexander Krause; Philippe Leissner; Alain Puisieux
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

6.  ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.

Authors:  Guoliang Qing; Bo Li; Annette Vu; Nicolas Skuli; Zandra E Walton; Xueyuan Liu; Patrick A Mayes; David R Wise; Craig B Thompson; John M Maris; Michael D Hogarty; M Celeste Simon
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

Review 7.  Neuroblastoma and MYCN.

Authors:  Miller Huang; William A Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

8.  LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors.

Authors:  Ting Tao; Hui Shi; Luca Mariani; Brian J Abraham; Adam D Durbin; Mark W Zimmerman; John T Powers; Pavlos Missios; Kenneth N Ross; Antonio R Perez-Atayde; Martha L Bulyk; Richard A Young; George Q Daley; A Thomas Look
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

9.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.

Authors:  Roderik M Kortlever; Nicole M Sodir; Catherine H Wilson; Deborah L Burkhart; Luca Pellegrinet; Lamorna Brown Swigart; Trevor D Littlewood; Gerard I Evan
Journal:  Cell       Date:  2017-11-30       Impact factor: 41.582

10.  MYCN amplification and ATRX mutations are incompatible in neuroblastoma.

Authors:  Maged Zeineldin; Sara Federico; Xiang Chen; Yiping Fan; Beisi Xu; Elizabeth Stewart; Xin Zhou; Jongrye Jeon; Lyra Griffiths; Rosa Nguyen; Jackie Norrie; John Easton; Heather Mulder; Donald Yergeau; Yanling Liu; Jianrong Wu; Collin Van Ryn; Arlene Naranjo; Michael D Hogarty; Marcin M Kamiński; Marc Valentine; Shondra M Pruett-Miller; Alberto Pappo; Jinghui Zhang; Michael R Clay; Armita Bahrami; Peter Vogel; Seungjae Lee; Anang Shelat; Jay F Sarthy; Michael P Meers; Rani E George; Elaine R Mardis; Richard K Wilson; Steven Henikoff; James R Downing; Michael A Dyer
Journal:  Nat Commun       Date:  2020-02-14       Impact factor: 14.919

View more
  13 in total

1.  Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.

Authors:  Qi-Lei Han; Xiang-Lei Zhang; Peng-Xuan Ren; Liang-He Mei; Wei-Hong Lin; Lin Wang; Yu Cao; Kai Li; Fang Bai
Journal:  Acta Pharmacol Sin       Date:  2022-10-07       Impact factor: 7.169

2.  MYCN protein stability is a better prognostic indicator in neuroblastoma.

Authors:  Yi Yang; Jie Zhao; Yingwen Zhang; Tianyue Feng; Bo Yv; Jing Wang; Yijin Gao; Minzhi Yin; Jingyan Tang; Yanxin Li
Journal:  BMC Pediatr       Date:  2022-07-11       Impact factor: 2.567

3.  CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma.

Authors:  Eelin Tan; Khurshid Merchant; Bhanu Prakash Kn; Arvind Cs; Joseph J Zhao; Seyed Ehsan Saffari; Poh Hwa Tan; Phua Hwee Tang
Journal:  Childs Nerv Syst       Date:  2022-04-23       Impact factor: 1.532

4.  Pyroptosis-Related Gene Signature Predicts the Prognosis and Immune Infiltration in Neuroblastoma.

Authors:  Wanrong Li; Xin Li; Yuren Xia; Jian Wang
Journal:  Front Genet       Date:  2022-05-19       Impact factor: 4.772

5.  Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma.

Authors:  Peter Macsek; Jan Skoda; Maria Krchniakova; Jakub Neradil; Renata Veselska
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

6.  Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases.

Authors:  Fan Li; Weiling Zhang; Huimin Hu; Yi Zhang; Jing Li; Dongsheng Huang
Journal:  Cancer Manag Res       Date:  2022-01-06       Impact factor: 3.989

7.  Antitumor Effect of Saikosaponin A on Human Neuroblastoma Cells.

Authors:  Tan Cheng; Muying Ying
Journal:  Biomed Res Int       Date:  2021-09-01       Impact factor: 3.411

Review 8.  Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.

Authors:  Roberto Ciaccio; Piergiuseppe De Rosa; Sara Aloisi; Marta Viggiano; Leonardo Cimadom; Suleman Khan Zadran; Giovanni Perini; Giorgio Milazzo
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

9.  MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma.

Authors:  Fangjin Lu; Bin Mu; Ge Jin; Lin Zhu; Ping Mu
Journal:  Oncol Res       Date:  2021-12-22       Impact factor: 4.938

Review 10.  Therapeutic Targeting of Exportin-1 in Childhood Cancer.

Authors:  Basia Galinski; Thomas B Alexander; Daniel A Mitchell; Hannah V Chatwin; Chidiebere Awah; Adam L Green; Daniel A Weiser
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.